PeDRA 2025Abstract 069Clinical trial
Lebrikizumab Improves Anxiety and Depression Symptoms of Adolescents With Moderate-to-Severe Atopic Dermatitis
Results From a 52-Week, Open-label, Phase 3 Study
Geng B, Mehta V, Paller A, Alexis A, Irvine A, Flohr C, Torrelo A, Dawson Z, Pierce E, Agell H, Zhang H, Qiao M
PeDRA Annual Conference 2025Minneapolis, 9–11 Oct 2025 · published in JID 9 Mar 2026
Topics: Atopic dermatitis & eczemaPediatric dermatology
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/s0022-202x(26)00605-6 · Not in PubMed: details from Crossref